Jennifer R. Brown, MD, PhD, on Treating CLL With the Novel Immunotherapy KTE-X19

Posted: Tuesday, September 3, 2019

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, describes the immunotherapy KTE-X19, its proposed mechanism in relapsed or refractory chronic lymphocytic leukemia, and how it might be incorporated into a therapeutic plan.